Prab: CSV import

2025-02-13T03:39:02Z

CSV import

← Older revision		Revision as of 03:39, 13 February 2025
Line 1:		Line 1:
	~~'''~~Encenicline''' (INN, USAN; code name EVP-6124) is a synthetic molecule and a novel pharmacological agent that acts as a selective agonist for the [[alpha-7 nicotinic acetylcholine receptor]] (α7 nAChR). It is primarily researched for its potential therapeutic applications in neurodegenerative conditions, particularly [[Alzheimer's disease]] and [[schizophrenia]], where cognitive functions are significantly impaired. Encenicline has been shown to enhance cognitive performance in preclinical studies and has proceeded through various phases of clinical trials to determine its efficacy and safety in humans.		== Encenicline ==

	~~==Mechanism of Action==~~		[[File:Encenicline.svg\|thumb\|right\|Chemical structure of Encenicline]]
	Encenicline ~~functions by selectively activating the α7 nAChR, a subtype of nicotinic receptors that is predominantly expressed in the brain~~. ~~These receptors are ligand-gated ion channels that, upon activation by endogenous neurotransmitter acetylcholine or exogenous agonists like encenicline, allow the influx~~ of cations such as calcium, sodium, and potassium. This action can modulate neurotransmitter release and enhance synaptic plasticity, which is crucial for learning and memory processes. The selective activation of α7 nAChR by encenicline is believed to improve cognitive functions without eliciting the adverse effects commonly associated with non-selective activation of other nicotinic receptors.

	~~==Clinical Trials and Research==~~		'''Encenicline''' is a pharmaceutical compound that acts as a selective partial agonist of the [[_7 nicotinic acetylcholine receptor]]. It has been investigated for its potential use in the treatment of [[cognitive impairment]] associated with [[schizophrenia]] and [[Alzheimer's disease]].
	Encenicline has been ~~the subject of multiple phase I, II, and III clinical trials to assess~~ its ~~safety, tolerability, and efficacy in improving cognitive impairment in Alzheimer's disease and schizophrenia. Early-phase clinical trials demonstrated a favorable safety profile and indicated~~ potential ~~cognitive benefits without significant adverse effects. However, in later-phase trials, particularly~~ in the treatment of cognitive impairment associated with schizophrenia~~, the results have been mixed, with some studies not meeting their primary endpoints~~.

	~~Despite these challenges, research on encenicline continues, with a focus on optimizing dosing regimens, understanding its mechanism~~ of ~~action in the context of complex neurodegenerative diseases, and identifying patient populations that may benefit most from this treatment.~~		== Mechanism of Action ==

	~~==Potential Therapeutic Applications==~~		Encenicline binds to the [[_7 nicotinic acetylcholine receptor]], which is a subtype of the [[nicotinic acetylcholine receptor]] family. These receptors are ion channels that, when activated, allow the flow of ions such as [[calcium]] and [[sodium]] into the cell. The activation of these receptors is thought to enhance [[neurotransmission]] and improve cognitive function by modulating the release of [[neurotransmitters]] such as [[dopamine]], [[glutamate]], and [[acetylcholine]].
	The ~~primary therapeutic applications~~ of ~~encenicline are focused on neurodegenerative~~ and ~~neuropsychiatric disorders where~~ cognitive ~~functions are compromised:~~

	* '''Alzheimer's Disease:''' Encenicline has shown promise in improving cognitive functions such as memory, attention, and executive function in patients with mild to moderate Alzheimer's disease.		== Clinical Development ==
	* '''Schizophrenia:''' Given its potential to enhance cognitive performance, encenicline is also being explored as an adjunctive treatment for cognitive deficits in patients with schizophrenia.

	~~==Safety and Side Effects==~~		Encenicline has undergone several clinical trials to evaluate its efficacy and safety in treating cognitive deficits. Initial studies showed promise in improving cognitive performance in patients with [[schizophrenia]] and [[Alzheimer's disease]]. However, further trials were necessary to confirm these findings and to better understand the drug's safety profile.
	~~The safety profile of encenicline~~ has ~~been generally favorable in early~~ clinical trials~~, with most adverse effects being mild~~ to ~~moderate~~ in ~~severity~~. ~~Common side effects include nausea, vomiting,~~ and ~~headache~~. However, ~~as with all pharmacological treatments, careful monitoring and~~ further ~~research are~~ necessary to ~~fully~~ understand the ~~long-term~~ safety ~~and potential risks associated with encenicline therapy~~.

	==~~Future Directions~~==		== Potential Benefits ==
	The development of encenicline represents an ongoing effort to address the unmet need for effective treatments for cognitive impairment in neurodegenerative and neuropsychiatric disorders. Future research will likely focus on further elucidating its mechanism of action, optimizing its clinical efficacy through personalized medicine approaches, and exploring its potential benefits in other conditions characterized by cognitive dysfunction.

	~~{{Chem-stub}}~~		The potential benefits of encenicline include improved cognitive function, particularly in areas such as [[memory]], [[attention]], and [[executive function]]. These improvements could significantly enhance the quality of life for individuals suffering from cognitive impairments due to [[neurodegenerative diseases]] or [[psychiatric disorders]].

			== Side Effects ==

			Like many pharmaceuticals, encenicline may cause side effects. Commonly reported side effects include [[gastrointestinal disturbances]], such as [[nausea]] and [[vomiting]], as well as [[headache]] and [[dizziness]]. The safety and tolerability of encenicline continue to be evaluated in ongoing studies.

			== Research and Development ==

			Research into encenicline is part of a broader effort to develop new treatments for cognitive impairments. The focus on the [[_7 nicotinic acetylcholine receptor]] is due to its role in cognitive processes and its potential as a therapeutic target. Ongoing research aims to optimize the efficacy and safety of encenicline and similar compounds.

			== Related Pages ==

			* [[Nicotinic acetylcholine receptor]]
			* [[Cognitive impairment]]
			* [[Schizophrenia]]
			* [[Alzheimer's disease]]
			* [[Neurotransmitter]]

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Neuroscience]]		[[Category:Neuroscience]]
	[[Category:~~Alzheimer's disease]]~~		[[Category:Experimental drugs]]
	~~[[Category:Schizophrenia~~]]

Prab: CSV import

2024-03-22T07:20:09Z

CSV import

New page

'''Encenicline''' (INN, USAN; code name EVP-6124) is a synthetic molecule and a novel pharmacological agent that acts as a selective agonist for the [[alpha-7 nicotinic acetylcholine receptor]] (α7 nAChR). It is primarily researched for its potential therapeutic applications in neurodegenerative conditions, particularly [[Alzheimer's disease]] and [[schizophrenia]], where cognitive functions are significantly impaired. Encenicline has been shown to enhance cognitive performance in preclinical studies and has proceeded through various phases of clinical trials to determine its efficacy and safety in humans.

==Mechanism of Action==
Encenicline functions by selectively activating the α7 nAChR, a subtype of nicotinic receptors that is predominantly expressed in the brain. These receptors are ligand-gated ion channels that, upon activation by endogenous neurotransmitter acetylcholine or exogenous agonists like encenicline, allow the influx of cations such as calcium, sodium, and potassium. This action can modulate neurotransmitter release and enhance synaptic plasticity, which is crucial for learning and memory processes. The selective activation of α7 nAChR by encenicline is believed to improve cognitive functions without eliciting the adverse effects commonly associated with non-selective activation of other nicotinic receptors.

==Clinical Trials and Research==
Encenicline has been the subject of multiple phase I, II, and III clinical trials to assess its safety, tolerability, and efficacy in improving cognitive impairment in Alzheimer's disease and schizophrenia. Early-phase clinical trials demonstrated a favorable safety profile and indicated potential cognitive benefits without significant adverse effects. However, in later-phase trials, particularly in the treatment of cognitive impairment associated with schizophrenia, the results have been mixed, with some studies not meeting their primary endpoints.

Despite these challenges, research on encenicline continues, with a focus on optimizing dosing regimens, understanding its mechanism of action in the context of complex neurodegenerative diseases, and identifying patient populations that may benefit most from this treatment.

==Potential Therapeutic Applications==
The primary therapeutic applications of encenicline are focused on neurodegenerative and neuropsychiatric disorders where cognitive functions are compromised:

* '''Alzheimer's Disease:''' Encenicline has shown promise in improving cognitive functions such as memory, attention, and executive function in patients with mild to moderate Alzheimer's disease.
* '''Schizophrenia:''' Given its potential to enhance cognitive performance, encenicline is also being explored as an adjunctive treatment for cognitive deficits in patients with schizophrenia.

==Safety and Side Effects==
The safety profile of encenicline has been generally favorable in early clinical trials, with most adverse effects being mild to moderate in severity. Common side effects include nausea, vomiting, and headache. However, as with all pharmacological treatments, careful monitoring and further research are necessary to fully understand the long-term safety and potential risks associated with encenicline therapy.

==Future Directions==
The development of encenicline represents an ongoing effort to address the unmet need for effective treatments for cognitive impairment in neurodegenerative and neuropsychiatric disorders. Future research will likely focus on further elucidating its mechanism of action, optimizing its clinical efficacy through personalized medicine approaches, and exploring its potential benefits in other conditions characterized by cognitive dysfunction.

{{Chem-stub}}

[[Category:Pharmacology]]
[[Category:Neuroscience]]
[[Category:Alzheimer's disease]]
[[Category:Schizophrenia]]

Encenicline - Revision history

Prab: CSV import

Prab: CSV import